• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

J&J tops earnings estimates amid strong demand for cancer treatments

by January 22, 2025
written by January 22, 2025

Investing.com – Johnson & Johnson (NYSE:JNJ) posted fourth-quarter adjusted earnings and sales that topped analysts’ estimates, as the pharmaceutical firm was boosted by demand for its cancer treatments.

The drugmaker added that it now expects to deliver full-year sales of $90.9 billion to $91.7 billion in 2025, as well as $10.75 to $10.95 in adjusted earnings per share. Both the forecasts were also above expectations, according to LSEG figures cited by Reuters.

Fourth-quarter sales at J&J jumped by 5.3% versus the year-ago period to $22.52 billion, fueled in part by a 19% uptick in sales of its cancer drugs. Sales of its multiple myeloma treatment Darzalex in particular surged by almost 21% to over $3 billion.

Chief Financial Officer Joe Wolk added that its $13.1 billion deal to acquire heart health group Shockwave Medical (NASDAQ:SWAV) also bolstered its top-line returns during the quarter, Reuters reported. J&J said Shockwave contributed $258 million in sales for the quarter.

Strength at J&J’s medical technology division and innovative medicine unit helped counter a 14.7% dip in sales of its psoriasis treatment Stelara as well. Performance of the blockbuster drug has been dented by the emergence of copies in several markets, with other biosimilars due to be launched in the US this year.

J&J’s adjusted earnings during the fourth quarter came in at $2.04 per share. Although the figure, which included a $0.22 impairment charge related to the acquisition of medical device manufacturer V-Wave, was down 11% year-on-year, it was still higher than projections of $2.01.

Shares in J&J, which recently agreed to purchase neurological medicine manufacturer Intra-Cellular for $14.6 billion, were hovering around the flatline in premarket US trading on Wednesday.

(Reuters contributed reporting.)

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
GE Vernova misses earnings, revenue estimates in Q4; stock down
next post
J&J beats quarterly sales and profit estimates on cancer drug sales

You may also like

BASF results down on impairments, restructuring

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Ryanair cuts 2026 traffic forecast amid ongoing Boeing...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Procter & Gamble to cut 7,000 jobs as part of broader restructuring

      June 6, 2025
    • Shein and Temu see U.S. demand plunge as loophole for cheap goods closes

      June 6, 2025
    • Shein and Temu see U.S. demand plunge as loophole for cheap goods closes

      June 5, 2025
    • This California startup is cleaning water and removing CO₂ from the atmosphere — all at a reduced cost

      June 5, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (504)
    • Stock (6,426)

    Latest News

    • Procter & Gamble to cut 7,000 jobs as part of broader restructuring
    • Shein and Temu see U.S. demand plunge as loophole for cheap goods closes

    Popular News

    • Factbox-Most banks expect gold’s bull run to persist into 2025
    • Germany’s Scholz responds to Musk, saying freedom of speech must not back extreme-right

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy